Abstract Library

#2691 Somatostatin Analogs in Patients with Zollinger Ellison Syndrome (ZES): An Observational Study

Introduction: Zollinger Ellison syndrome (ZES) is a rare syndrome caused by gastrin hypersecretion from a primary neuroendocrine tumor (NET), usually located within the duodenum or into the pancreas. Gastrinomas have two important treatment goal: the control of the gastrin-excess state and the control of tumor growth.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: massironi s

Authors: Massironi S, Peracchi M, Elvevi A, Cristoferi L, Quatrini M,

Keywords: ZES, gastrinoma, somatostatin analogs,

#1756 Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety

Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: somatostatin analogs, MEN1, Zollinger-Ellison syndrome,

#1069 Gastric Neuroendocrine Neoplasms and Long-Term Proton Pump Inhibitors: Need for a Revision of Classifications?

Introduction: Gastric neuroendocrine neoplasm (gNENs) include three types: type 1 and 2 related to hypergastrinemia due to chronic atrophic gastritis(CAG) or Zollinger-Ellison syndrome (ZES) respectively, and type 3 normogastrinemic and more aggressive. Few cases of gNENs in patients taking proton pump inhibitors (PPI) have been reported

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Cavalcoli f

Authors: Cavalcoli F, Zilli A, Conte D, Ciafardini C, Massironi S,

Keywords: PPI, gNEN, classification, CAG,

#386 A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans

Introduction: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. PPI-induced achlorhydria increases circulating gastrin and chromogranin A (CGA). CGA is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). PPI-induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Raines D, Chester M, Diebold A, Mamikunian P, Anthony C,

Keywords: Chromogranin A, gastrin, pancreastatin, neuroendocrine tumor (NET),

#53 The rise and fall of chromogranin A as an indicator for NET

Introduction: There is now general awareness that treatment with proton pump inhibitors (ppi) may cause moderate rises in circulating concentrations of gastrin and/or chromogranin A (CgA), thus decreasing the specificity of these markers in the diagnosis of neuroendocrine tumors (NETs). Due to their high efficacy, proton pump inhibitors (ppi) are one of the most frequently prescribed classes of drugs worldwide. Several studies in various countries report that 30% or more of in-patients have been prescribed ppi. Patients who are suspected of having a neuroendocrine tumor (NET) often have gastrointestinal (GI) symptoms for which ppi are prescribed and therefore they may be already taking ppi when their first blood sample is assayed for NET markers. We previously encountered a case of extreme rise in CgA which flagged the possibility of a NET, but was later shown to be due to ppi therapy alone. We present CgA and gastrin data in relation to ppi therapy and withdrawal for this patient. In order to see if this was an isolated incident, we audited all laboratory requests for CgA/gastrin in a two-year period and monitored those that provided details of ppi treatment/withdrawal.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Armstrong L, Ryan K, Ardill J,

Keywords: Chromogranin A, proton pump inhibitors, gastrin, audit, case report,